当前位置:循环首页>正文

[AHA2006]N-Terminal proB-type Natriuretic Peptide Improves the Management of Patients with Suspected Acute Heart FailurePrimary Results of the Canadian Multicenter IMPROVE-CHF Study加拿大多中心IMPROVE-CHF 研究初步结果表明N端BNP前体蛋白可改善对疑似急性心衰患者的处置

作者:国际循环网   日期:2006/12/18 0:00:00

国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

Gordon W. Moe, MD; Jonathan Howlett, MD; Hanna Zowall, PHD; for the Canadian Multicenter IMPROVE-CHF Study Investigators From the University of Toronto, St. Michael"s Hospital, Toronto, Ontario, Canada (G.W.M.); McGill University, Montreal, Quebec, Canada (H.Z.); and Dalhousie University, Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia, Canada (J.H.) Correspondence to Gordon W. Moe, MD, St Michael’s Hospital, 30 Bond Street, Toronto, Ontario, Canada, M5B1W8. Email moeg@smh.toronto.on.ca 

Background 
Acute heart failure (HF) has emerged to be a public health problem worldwide. In the United States, hospitalizations for HF has increased from 377,000 in 1979 to 1,093,000 in 2003.1,2 In Canada, a country that adopts a system of universal health insurance,3 patients admitted with acute HF experience high in-hospital and one-year mortality4-7 and early readmission to hospital for HF is frequent.8,9 B-type natriuretic peptide (BNP) and the amino-terminal fragment of the precursor protein (NT-proBNP), have been shown to be useful in establishing the diagnosis of acute HF and providing short-term prognostic information in patients presenting to urgent care settings with dyspnea.10-14 However, previous landmark trials, particularly those of NT-proBNP, had either involved relatively small number of patients15,16 or were conducted in a single institution.17,18 Furthermore, the larger-scale studies of BNP and NT-proBNP were conducted in centers in the United States where per capita health care spending is about twice of that of Canada.19 These published data, while exceedingly important, are not necessarily applicable to countries like Canada which has a publicly funded universal coverage system that
 Methods and Results 
In a Canadian multicenter trial, we tested the hypothesis that NT-proBNP testing improves the management of patients presenting with dyspnea to emergency departments (EDs) in a universal health coverage model by prospectively evaluating the diagnostic of NT-proBNP and the clinical and economic impact of management guided by NT-proBNP results. A total of 501 patients presenting with dyspnea to seven Canadian EDs were studied. Physicians committed to a diagnosis later adjudicated by cardiologists blinded to assay results. Patients were randomized to usual care or NT-proBNP-guided management. Preliminary results are shown in the tables and figures. Median NT-proBNP level among the 231 subjects (46%) with diagnoses of HF was 3717 pg/ml versus 340 pg/ml in those without, P<0.00001. In establishing a diagnosis, adding NT-proBNP to clinical judgment enhanced accuracy, the area under the receiver-operating characteristic curve increased from 0.82 to 0.90, P<0.00001. Knowledge of NT-proBNP results reduced the duration of ED visit (6.3 to 5.6 hours, P =0.038), number of patients re-hospitalized (51 to 33, P =0.044) and cost of all ED visits and hospitalizations (US

[1]  [2]  [3]  下一页

版面编辑:国际循环



IMPROVE-CHF研究心力衰竭NT-proBNPaha2006专家在线

分享到: 更多


设为首页 | 加入收藏 | 关于我们 | 联系方式 | 招贤纳士
声明:国际循环网( www.icirculation.com)对刊载的所有文章、视频、幻灯、音频等资源拥有全部版权。未经本站许可,不得转载。
京ICP备15014970号-5  互联网药品信息服务资格证书编号(京)-非经营性-2017-0063  京公网安备 11010502033353号  增值电信业务经营许可证:京ICP证150541号
国际循环 版权所有   © 2004-2024 www.icirculation.com All Rights Reserved
公司名称:北京美赞广告有限公司 公司地址:北京市朝阳区朝阳门北大街乙12号天辰大厦1座1409 电话:010-51295530